MODULATION OF OVARIECTOMY-RELATED BONE LOSS BY PARATHYROID-HORMONE IN RATS

被引:49
作者
KALU, DN [1 ]
ECHON, R [1 ]
HOLLIS, BW [1 ]
机构
[1] MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29425
关键词
Bone loss; Ovariectomy; Parathyroid hormone;
D O I
10.1016/0047-6374(90)90114-U
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Studies were carried out to examine whether parathyroid hormone (PTH) will prevent the age-related bone loss that results from ovarian hormone deficiency and to explore the mechanism of its action. Ovariectomy caused a significant decrease in bone density in the distal metaphysis and mid-diaphysis, but not in the vertebra and proximal metaphysis. The decrease was prevented by PTH injection and in all the bones examined PTH administration increased bone density and bone calcium content above the levels in sham-operated controls. Similar findings were made in bone hydroxyproline levels. PTH treated ovariectomized animals had lower serum 25(OH)vitamin D and higher 1,25(OH)2 vitamin D levels than ovariectomized and sham operated animals that received solvent vehicle. Compared to the sham operated controls, ovariectomy caused a 4.5-fold increase in the number of tartrate resistant acid phosphatase (TRAP) positive multinuclear cells. This increase did not occur in PTH-treated animals. We conclude that PTH is effective in preventing ovarian hormone deficiency bone loss in rats. PTH may mediate this effect partly by stimulating osteoblastic bone formation and partly by increasing 1,25(OH)2 vitamin D-mediated calcium absorption. The data from TRAP positive multinuclear cells indicate that an etiologic component of ovarian hormone deficiency bone loss is the expansion of a pool of osteoclast progenitors and that the bone anabolic action of PTH involves, in part, a decrease in bone resorption as a result of the suppression of the proliferation of osteoclast progenitors. © 1990.
引用
收藏
页码:49 / 62
页数:14
相关论文
共 33 条
[11]   INCREASE OF VERTEBRAL DENSITY BY COMBINATION THERAPY WITH PULSATILE 1-38HPTH AND SEQUENTIAL ADDITION OF CALCITONIN NASAL SPRAY IN OSTEOPOROTIC PATIENTS [J].
HESCH, RD ;
BUSCH, U ;
PROKOP, M ;
DELLING, G ;
RITTINGHAUS, EF .
CALCIFIED TISSUE INTERNATIONAL, 1989, 44 (03) :176-180
[12]   THE RELATIONSHIP BETWEEN CHANGES IN FEMORAL BONE-DENSITY AND CALCIUM BALANCE IN PATIENTS WITH INVOLUTIONAL OSTEOPOROSIS TREATED WITH HUMAN PARATHYROID-HORMONE FRAGMENT (HPTH-1-34) [J].
HESP, R ;
HULME, P ;
WILLIAMS, D ;
REEVE, J .
METABOLIC BONE DISEASE & RELATED RESEARCH, 1981, 2 (05) :331-334
[13]   HUMAN PARATHYROID HORMONE-(1-34) INCREASES BONE MASS IN OVARIECTOMIZED AND ORCHIDECTOMIZED RATS [J].
HOCK, JM ;
GERA, I ;
FONSECA, J ;
RAISZ, LG .
ENDOCRINOLOGY, 1988, 122 (06) :2899-2904
[14]  
HOLLIS BW, 1985, CLIN CHEM, V31, P1815
[15]  
HOLLIS BW, 1986, CLIN CHEM, V32, P2060
[16]  
HORI M, 1988, BONE MINER, V3, P193
[17]  
Jaffe HL, 1933, ARCH PATHOL, V16, P63
[18]   THE AGED RAT MODEL OF OVARIAN HORMONE DEFICIENCY BONE LOSS [J].
KALU, DN ;
LIU, CC ;
HARDIN, RR ;
HOLLIS, BW .
ENDOCRINOLOGY, 1989, 124 (01) :7-16
[19]  
KALU DN, 1970, LANCET, V1, P1363
[20]  
KALU DN, 1989, J BONE MINER RES S1, V4, pS236